Adenoviral vector vaccine, and preparation method and use thereof
By mutation of negatively charged amino acids of adenovirus hexon protein, the surface charge is changed, and the thrombosis risk caused by the interaction between adenovirus vector and PF4 is solved, safe and efficient immunization and vaccine vectors are achieved, and the body fluids and cells are stimulated. and mucosal immune response.
Patent Information
- Application Number
- PCT/CN2024/096745
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-02
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
Adenovirus vectors have a risk of pre-existing immunity and replication capacity contamination in their application, leading to side effects such as thrombosis. The interaction of existing adenovirus vectors with PF4 may cause thrombocytopenia, and existing studies lack understanding of adenovirus risk.
By mutation of negatively charged amino acids in adenovirus hexon proteins, changing their surface charges to reduce the probability of interaction with PF4, recombinant adenovirus vectors are developed for gene therapy, tumor immunity, and antiviral immunization, and Immune response is stimulated through mucosal administration.
It reduces the probability of adenovirus causing thrombotic events, improves immune effects, reduces side effects, provides a safe and efficient vaccine carrier, and stimulates multi-level immune response through inhalation administration.
Smart Images

Figure CN2024096745_05122024_PF_FP_ABST
Abstract
Description
Adenovirus vector vaccine and its preparation method and application Technical Field
[0001] The present invention relates to the field of vaccine technology, and more particularly to a method for preparing and applying an artificially modified adenovirus vector vaccine, and more particularly to a non-injectable adenovirus vector vaccine comprising a method for reducing the surface charge of the adenovirus vector. Background Art
[0002] Adenoviruses (Ads) comprise a large family of double-stranded DNA viruses found in amphibians, birds, and mammals, possessing a non-enveloped, icosahedral capsid structure. Their well-characterized molecular genetics make adenovirus vectors promising candidates for use as vaccine carriers. Production of recombinant adenovirus vectors relies on the use of packaging cell lines capable of complementing the functions of adenoviral gene products. Adenoviruses lack an envelope, exhibit icosahedral symmetry, and possess 252 capsomers. The 20 apical capsomers consist of 12 pentons, each with two fibers. In addition to the pentons, there are 240 non-apical capsomers, called hexons, which carry primary genus- and subgenus-specific antigenic determinants and secondary species-specific antigenic determinants. The structural specificity of the hexon protein encodes neutralizing epitopes that participate in immune responses. To date, 101 adenovirus species have been isolated from these hosts.
[0003] Currently, two well-characterized human subgroup C adenovirus serotypes (i.e., hAd2 and hAd5) are widely used as the source of the viral backbone for most adenoviral vectors used for gene therapy. Replication-defective human adenoviral vectors have also been tested as vaccine vectors for the delivery of various immunogens derived from various infectious agents (e.g., viral, parasitic, or bacterial pathogens) and tumor cells, including tumor-associated antigens (TAAs). With the increasing use of replication-defective human adenoviral vectors, two related issues are the risk of pre-existing immunity and contamination by replication-competent adenovirus (RCA).
[0004] In order to solve the above problems, the emergence of chimpanzee adenovirus vectors or other rare human serotypes of human adenovirus vectors provides a path. However, the development of new types of adenovirus vectors has caused many safety issues. In the development of the new crown vaccine, AstraZeneca's vaccine uses chimpanzee ChAdOx1 adenovirus as a vector, which has been mired in thrombosis suspicions. The European Medicines Agency issued a statement saying that its subordinate Pharmacovigilance Risk Assessment Committee determined that abnormal thrombosis symptoms accompanied by thrombocytopenia should be listed as a very rare side effect of AstraZeneca's new crown vaccine. Later, a joint research team from Cardiff University in the UK and the United States published an article in Science Advances that revealed the mechanism by which the AstraZeneca vaccine may cause thrombosis. The British and American joint team believes that the culprit causing the thrombosis is likely to be the interaction between the adenovirus vector ChAdOx1 used in the AstraZeneca vaccine and PF4 (platelet factor 4), which mistakenly triggers the immune system to release anti-PF4 antibodies and accumulate in the blood. PF4 is involved in the pathological mechanism of HIT (thrombocytopenia), which has clinical manifestations similar to TTS (thrombocytopenia syndrome). ChAdOx1 can also form a stable complex with PF4 and has high electronegativity. In a Brownian dynamics (BD) simulation, freely diffusing PF4 often contacts the capsid surface of ChAdOx1 between hexons, most commonly at the interface of three hexons. In contrast, Ad-26, another adenovirus vector used in the Johnson & Johnson COVID-19 vaccine, also forms contact with PF4, but the frequency is lower. This led the US Centers for Disease Control and Prevention and the Food and Drug Administration to recommend suspending the use of the vaccine. Research at the University of Nebraska Medical Center showed that the cause of the Johnson & Johnson COVID-19 vaccine causing blood clots is basically the same as that of the AstraZeneca COVID-19 vaccine.
[0005] While adenoviruses have been used for a long time, current research clearly lacks understanding of their risks, and adenoviruses present unforeseen risks. Based on the problems encountered with various adenoviral vectors, the inventors have dedicated themselves to modifying adenoviral vectors to address their safety concerns.
[0006] Summary of the Invention
[0007] To achieve the above objectives, the inventors conducted multiple biological experiments on adenovirus modification and clarified the modification method of adenovirus vectors through multiple experiments. A recombinant adenovirus and a modification method thereof are provided.
[0008] Specifically provided is a recombinant adenovirus, wherein one or more negatively charged amino acids in the hexon protein of the adenovirus are mutated into neutral amino acids or positively charged amino acids.
[0009] The mutation region of the adenovirus hexon protein is the hypervariable region HVR of the adenovirus hexon protein;
[0010] The hypervariable region HVR of the adenovirus hexon protein includes one or more of HVR1, HVR2, HVR3, HVR4, HVR5, HVR6, and HVR7;
[0011] The negatively charged amino acids are aspartic acid and / or glutamic acid;
[0012] The neutral amino acid is selected from one or more of asparagine, glutamine, glycine, alanine, leucine, isoleucine, valine, cysteine, methionine, threonine, serine, and phenylalanine;
[0013] The neutral amino acid is selected from one or more of valine V, leucine L, asparagine N, glutamine Q, and isoleucine I;
[0014] The positively charged amino acid is selected from one or more of arginine R, lysine K, and histidine H;
[0015] The adenovirus hexon binds to PF4. The front and middle segments of the hexon contain numerous antigenic peaks and dense hydrophilic peaks. These regions contain numerous conserved regions with a high concentration of hydrophobic amino acids. These amino acids form the key building blocks of the hexon's spatial structure and are crucial for the formation of its secondary structure. Modifications targeting adenovirus must maintain a reasonable structure, ensuring its basic functions while addressing the interaction with PF4.
[0016] The recombinant adenoviral vectors of the present invention can be used for gene therapy, tumor immunization, and / or antiviral immunization. The recombinant adenoviral vectors of the present invention can be used for gene delivery. Adenoviral particles can be specifically directed to target cells of interest. The adenovirus binds to the specific target cells through capsid-receptor binding or other means and delivers the transgene.
[0017] The present invention also provides a composition comprising the recombinant adenovirus vector transformed by the above method.
[0018] The beneficial effects of the present invention include:
[0019] 1. The present invention provides a recombinant adenovirus. The surface charge of the recombinant adenovirus is changed, which can reduce the probability of interaction with PF4, solve the safety problem of adenovirus, and reduce the probability of thrombotic events caused by adenovirus during use.
[0020] 2. In one aspect of the present invention, the recombinant adenovirus vector of the present invention is prepared into a vaccine vector for delivering various immunogens, and the immune effect is better than that of the existing commonly used adenovirus vectors.
[0021] 3. In one aspect of the present invention, the recombinant adenovirus vector of the present invention can be used for gene therapy, tumor immunization and / or antiviral immunization, and can be used for gene delivery. Adenovirus particles can be specifically directed to target cells of interest, and the adenovirus binds to the specific target cells through capsid-receptor binding or other means and delivers the transgene.
[0022] 4. In one aspect of the present invention, the composition prepared based on the recombinant adenovirus vector of the present invention has fewer side effects and higher safety in clinical applications.
[0023] 5. In one aspect of the present invention, modified recombinant adenoviruses can be developed into mucosal formulations. For example, these can be administered via inhalation, simulating the viral infection process and stimulating an immune response. This avoids local adverse reactions such as injection site pain associated with intramuscular injection. By inhaling the vaccine into the lungs, the aerosolized vaccine can travel through the respiratory tract and ultimately reach the lungs, generating both humoral and cellular immunity while also stimulating respiratory mucosal immunity. The mucosal formulations of the present invention offer not only improved compliance compared to injections but also lower dosages, and can produce a triple protective effect of humoral, cellular, and mucosal immunity. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1. Surface charges of chimpanzee adenovirus vector ChAdOx1 with different HVR mutations
[0025] Figure 2. Virus titers of chimpanzee adenovirus vector ChAdOx1 with different HVR mutations
[0026] Figure 3. Surface charge of chimpanzee adenovirus vector ChAdOx1 with combined mutations in HVR2 and HVR7 regions.
[0027] Figure 4. Virus titers of chimpanzee adenovirus vector ChAdOx1 HVR2 and HVR7 combined mutations
[0028] Figure 5. Surface charge of chimpanzee adenovirus vector ChAdOx1 with combined mutations in HVR2 and HVR7 (different neutral amino acids)
[0029] Figure 6. Viral titers of chimpanzee adenovirus vector ChAdOx1 with combined mutations in HVR2 and HVR7 (different neutral amino acids)
[0030] Figure 7. Surface charge of chimpanzee adenovirus vector ChAdOx1 HVR1 / 2 / 5 / 7 combined mutations
[0031] Figure 8. Chimpanzee adenovirus vector ChAdOx1 HVR1 / 2 / 5 / 7 combined mutant virus titer DETAILED DESCRIPTION
[0032] Unless otherwise defined, all scientific and technical terms used in the present invention have the same meanings as commonly understood by one of ordinary skill in the art to which the present invention relates.
[0033] As used herein, the term "recombinant" implies that it has been artificially modified, ie, it is not a naturally occurring wild-type adenovirus.
[0034] As used herein, the term "recombinant adenovirus" is based on an adenovirus as used herein, derived at least in sequence from the wild type. This can be achieved by molecular cloning using the wild type genome or a portion thereof as starting material. The known sequence of the wild type adenovirus genome can also be used to regenerate (a portion of) the genome by DNA synthesis, which can be performed by commercial service companies in the field of DNA synthesis and / or molecular cloning (e.g., GeneArt, Invitrogen, GenScripts, Eurofins) using conventional procedures.
[0035] As used herein, the term "fragment" refers to a protein having an amino-terminal and / or carboxyl-terminal and / or internal deletions. It will be understood that for the purpose of inducing an immune response and generally for vaccination, a protein need not be full-length, nor need it have all of its wild-type functions, and fragments of the protein are equally applicable.
[0036] As used herein, the term "composition" refers to a vaccine or other composition prepared using a recombinant adenovirus capable of expressing a target gene by using adenovirus as a vector and recombining the target gene into the adenovirus genome.
[0037] As is conventional in the art, sequences herein are provided in a 5' to 3' direction.
[0038] A recombinant adenovirus, wherein one or more negatively charged amino acids in the adenovirus hexon protein are mutated to neutral or positively charged amino acids. The mutated region of the hexon protein is a hypervariable region (HVR) of the adenovirus hexon protein, including one or more of HVR1, HVR2, HVR3, HVR4, HVR5, HVR6, and HVR7; the mutated region of the hypervariable region (HVR) of the hexon protein includes at least HVR2 and HVR7.
[0039] The negatively charged amino acids are aspartic acid and / or glutamic acid;
[0040] The neutral amino acid is selected from one or more of asparagine, glutamine, glycine, alanine, leucine, isoleucine, valine, cysteine, methionine, threonine, serine, and phenylalanine, preferably one or more of valine, leucine, asparagine, and glutamine.
[0041] The positively charged amino acid is selected from one or more of arginine, lysine, and histidine.
[0042] At least one negatively charged amino acid in the hypervariable region (HVR) is mutated to a neutral amino acid.
[0043] The mutation regions of the adenovirus hexon protein are: D144 and / or E159 of HVR1 or their equivalent positions; D171 and / or D175 and / or D177 of HVR2 or their equivalent positions; D265 of HVR5 or their equivalent position; and / or D423 and / or D425 and / or E427 and / or E429 of HVR7 or their equivalent positions.
[0044] The adenovirus includes: simian adenovirus or human adenovirus.
[0045] The adenovirus includes any one of the seven subgroups A, B, C, D, E, F, and G of simian adenovirus, such as sAd1, sAd10, sAd11, sAd12, sAd13, sAd14, sAd15, sAd16, sAd18, sAd19, sAd2, sAd20, sAd23, sAd25, sAd26, sAd27, sAd28, sAd29, sAd3, sAd30, sAd31, sAd32, sAd33, sAd34, sAd35, sAd37, sAd38, sAd39, sAd4, sAd40, sAd43, sAd 44, sAd45, sAd46, sAd47, sAd48, sAd49, sAd6, sAd9, AdY25, AdC8, AdC22, AdC30, AdC37, AdC11, A dC3,AdC17,AdC19,AdC31,AdC20,AdC24,AdC16,AdC26,AdC82,AdC5,AdC7,AdC44,AdC38,AdC43 ,AdC63,AdC147,AdC73,AdC6,AdC55,AdC83,AdC143,AdC144,AdC145,AdC10,AdC28,AdC9,AdC6
[0046] Any of the seven subgroups A, B, C, D, E, F, and G of Rhesus adenovirus, such as RhAd51, RhAd52, RhAd53, RhAd54, RhAd55, RhAd56, RhAd57, RhAd58, RhAd59, RhAd60, RhAd61, RhAd62, RhAd63, RhAd64, RhAd65, RhAd66, RhAd67, and CyAd1
[0047] Any of the seven subgroups A, B, C, D, E, F, and G of Gorilla adenovirus, such as GoAd B20, GoAd B22, GoAd B21, GoAd B10, GoAd B11, GoAd B12, GoAd B13, GoAd B14, GoAd B19, GoAd E1, GoAd C10, GoAd C11, GoAd C12, GoAd C13, GoAd C14, GoAd C15, GoAd C16, GoAd C17, GoAd C18, GoAd1, and GoAd 2;
[0048] Any of the seven subgroups A, B, C, D, E, F, and G of baboon adenovirus, such as BaAd 3;
[0049] Any of the seven subgroups of human adenovirus, including A, B, C, D, E, F, and G, such as: Ad1, Ad10, Ad11, Ad12, Ad14, Ad15, Ad17, Ad18, Ad19, Ad2, Ad20, Ad21, Ad22, Ad23, Ad25, Ad26, Ad27, Ad28, Ad29, Ad3, Ad30, Ad31, Ad32, Ad33, Ad34, Ad35, Ad36, Ad38, Ad 39, any one of Ad4, Ad40, Ad41, Ad42, Ad43, Ad44, Ad45, Ad46, Ad47, Ad48, Ad49, Ad5, Ad50, Ad51, Ad52, Ad53, Ad54, Ad55, Ad56, Ad57, Ad6, Ad60, Ad61, Ad62, Ad63, Ad64, Ad65, Ad66, Ad68, Ad7, Ad89, Ad81, Ad86, Ad8E, AdD8 AdD9, AdD37, AdD10, AdD13, AdD110, and AdD109
[0050] The preparation method of recombinant adenovirus comprises introducing the recombinant adenovirus into complementary cells, culturing the cells and harvesting the virus.
[0051] Uses of recombinant adenovirus include gene therapy, tumor immunization and / or antiviral immunization.
[0052] The use of recombinant adenovirus includes eliciting primary immune response in humans or mammals, eliciting boosted immune response, and destroying host tolerance to self-antigens.
[0053] A composition comprising the recombinant adenovirus and at least one heterologous transgene. The heterologous transgene encapsulates a viral or bacterial antigen. The viral or bacterial antigen is selected from the group consisting of HIV, rabies virus, dengue virus, Ebola virus, coronavirus, human papillomavirus, hepatitis C virus, hepatitis B virus, rotavirus, measles virus, respiratory syncytial virus (RSV), herpes zoster virus (VZV), cytomegalovirus, herpes simplex virus type 2, Epstein-Barr virus, human metapneumovirus, parainfluenza virus, influenza virus, Trypanosoma cruzi and Plasmodium falciparum, Mycobacterium tuberculosis, Streptococcus pneumoniae, Moraxella catarrhalis, NTHi Haemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Staphylococcus aureus, Helicobacter pylori, and Chlamydia trachomatis.
[0054] The composition includes pharmaceutically acceptable excipients, such as one or more of a buffer, a protective agent, a stabilizer, a surfactant, an osmotic pressure regulator, an adjuvant, a preservative, and an inactivator. The buffer includes one or more of HEPES, HIS, TRIS, PB, succinic acid, and citric acid; the protective agent includes one or more of gelatin, ethanol, diethylaminotetraacetic acid (EDTA), disodium diethylaminotetraacetic acid (EDTA-2Na), and magnesium chloride; the stabilizer includes one or more of sucrose, mannitol, fucose, and maltose; the surfactant includes one or more of Tween, Span, and glycerol; the osmotic pressure regulator includes sodium chloride or may be omitted; and the excipient components include one or more of mannitol, sucrose, sodium chloride, magnesium chloride, HEPES, polysorbate 80, and glycerol.
[0055] The composition can be prepared as a mucosal immune preparation, a humoral immune preparation, a cellular immune preparation, or a skin immune preparation. Mucosal immune preparations are in liquid, solid, semisolid, gaseous, or inhaled dosage forms. The composition can be administered by intravenous injection, intramuscular injection, subcutaneous injection, oral administration, buccal administration, sublingual administration, rectal administration, respiratory administration, or transdermal administration. For respiratory administration, oral inhalation, nasal inhalation, or inhalation after atomization via a nebulizer device is employed. The unit dose of the composition is 0.05-5 ml, preferably 0.1-1 ml.
[0056] The uses of the composition include use in medicine, use in delivering transgenes into host cells, use in eliciting a primary immune response in humans or animals to treat or prevent at least one disease, use in enhancing the immune response in humans or animals, and use in inducing an immune response in humans or animals to break tolerance to self-antigens.
[0057] A method for producing a composition comprises providing nucleic acid of a protein or a fragment thereof of a heterologous gene, propagating the recombinant adenovirus in a host cell, isolating and purifying the recombinant adenovirus, and formulating the recombinant adenovirus into a pharmaceutically acceptable composition.
[0058] To further demonstrate the efficacy of the present invention, in certain embodiments, a recombinant chimpanzee adenovirus ChAdOx1 (SEQ.NO.1) is provided, wherein one or more negatively charged amino acids in the hexon protein of the ChAdOx1 adenovirus are mutated to neutral amino acids or positively charged amino acids. The mutations of the negatively charged amino acids in the hexon protein of the recombinant chimpanzee adenovirus ChAdOx1 are specifically: SEQ.NO.2-SEQ.NO.15
[0059] The hypervariable region HVR of the hexon protein includes one or more negatively charged amino acids in HVR1, HVR2, HVR5, and HVR7 mutated to neutral amino acids or positively charged amino acids.
[0060] The negatively charged amino acids of the recombinant chimpanzee adenovirus ChAdOx1 hexon protein are D144 and / or E159 of HVR1; the negatively charged amino acids of the hexon protein are D171 and / or D175 and / or D177 of HVR2; the negatively charged amino acids of the hexon protein are D265 of HVR5; the negatively charged amino acids of the hexon protein are D423 and / or D425 and / or E427 and / or E429 of HVR7;
[0061] The neutral amino acid after the negatively charged amino acid of the recombinant chimpanzee adenovirus ChAdOx1 hexon protein is mutated is one or more of valine, leucine, asparagine, and glutamine. The positively charged amino acid is selected from one or more of arginine R, lysine K, and histidine H.
[0062] The mutation region of the hypervariable region HVR of the hexon protein includes at least HVR2 and HVR7. In certain embodiments, the mutation of the negatively charged amino acids of the recombinant chimpanzee adenovirus ChAdOx1 hexon protein is specifically: SEQ.NO.16-SEQ.NO.38
[0063] In certain embodiments, a recombinant chimpanzee adenovirus ChAdOx1 is provided, wherein the hypervariable region HVR of the hexon protein of the ChAdOx1 adenovirus includes HVR1, HVR2, HVR5, and HVR7, in which one or more negatively charged amino acids are mutated to positively charged amino acids, SEQ.NO.18-SEQ.NO.30.
[0064] In certain embodiments, a recombinant chimpanzee adenovirus ChAdOx1 is provided, wherein the mutation region of the hexon protein of the ChAdOx1 adenovirus includes the hypervariable regions HVR1, HVR2 and HVR7 (SEQ.NO.39), HVR2, HVR5 and HVR7 (SEQ.NO.40) or HVR1HVR7, HVR2, HVR5 and HVR7 (SEQ.NO.41-SEQ.NO.50).
[0065] In certain embodiments, the collected adenovirus is further purified. Adenovirus purification can be performed in several steps, including purification, ultrafiltration, diafiltration, or chromatographic separation. Purification can be performed by filtration to remove cell debris and other impurities from the cell lysate. Ultrafiltration is used to concentrate the viral solution. Diafiltration or buffer exchange using an ultrafilter are methods for removing and exchanging salts, sugars, and the like. One of ordinary skill in the art will know how to find optimal conditions for each purification step.
[0066] A composition comprises the recombinant chimpanzee adenovirus vector transformed by the above method.
[0067] Specifically, the viral or bacterial antigens encapsulated by the above-mentioned transgene are selected from: HIV, rabies virus, dengue virus, Ebola virus, coronavirus, human papillomavirus, hepatitis C virus, hepatitis B virus, rotavirus, measles virus, respiratory syncytial virus (RSV), herpes zoster virus (VZV), cytomegalovirus, herpes simplex virus type 2, Epstein-Barr virus, human metapneumovirus, parainfluenza virus, influenza virus, Trypanosoma cruzi and Plasmodium falciparum, Mycobacterium tuberculosis, Streptococcus pneumoniae, Moraxella catarrhalis, NTHi Haemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Staphylococcus aureus, Helicobacter pylori, and one or more of Chlamydia trachomatis.
[0068] The composition of the present invention includes pharmaceutically acceptable excipients, such as one or more of a buffer, a protective agent, a stabilizer, a surfactant, an osmotic pressure regulator, an adjuvant, a preservative, and an inactivator. The buffer includes one or more of HEPES, HIS, TRIS, PB, succinic acid, and citric acid; the protective agent includes one or more of gelatin, ethanol, diethylaminotetraacetic acid (EDTA), disodium diethylaminotetraacetic acid (EDTA-2Na), and magnesium chloride; the stabilizer includes one or more of sucrose, mannitol, fucose, and maltose; the surfactant includes one or more of Tween, Span, and glycerol; the osmotic pressure regulator includes sodium chloride or may be omitted; and the excipient components include one or more of mannitol, sucrose, sodium chloride, magnesium chloride, HEPES, polysorbate 80, and glycerol.
[0069] The composition of the present invention can be prepared into mucosal immune preparations, humoral immune preparations, cellular immune preparations, and skin immune preparations. The mucosal immune preparations are in the form of liquid, solid, semi-solid, gaseous, or inhaled dosage forms.
[0070] The composition of the present invention can be administered by intravenous injection, intramuscular injection, subcutaneous injection, oral administration, buccal administration, sublingual administration, rectal administration, respiratory tract administration, and transdermal administration. Respiratory tract administration can be inhaled through the mouth, through the nose, or after atomization by an atomizer.
[0071] The composition of the present invention has a unit dose of 0.05-5 ml, preferably 0.1-1 ml.
[0072] The uses of the composition of the present invention include use in medicine, use in delivering transgenes into host cells, use in eliciting a primary immune response in humans or animals to treat or prevent at least one disease, use in enhancing the immune response in humans or animals, and use in inducing an immune response in humans or animals to break tolerance to self-antigens.
[0073] The method for producing the composition comprises providing nucleic acid of a protein or a fragment thereof of a heterologous gene, propagating the replication-deficient chimpanzee recombinant adenovirus in a host cell, isolating and purifying the recombinant adenovirus, and formulating the recombinant adenovirus into a pharmaceutically acceptable composition.
[0074] As used herein, a subject is preferably a mammal, such as a rodent, e.g., a mouse, a cotton rat, or a non-human primate, or a human. The subject is preferably a human subject. The subject can be of any age, e.g., from about 1 month old to 100 years old, e.g., from about 2 months old to about 80 years old, e.g., from about 1 month old to about 3 years old, from about 3 years old to about 50 years old, from about 50 years old to about 75 years old, etc.
[0075] The recombinant adenovirus of the present invention is further constructed into a recombinant adenovirus containing viral or bacterial antigens, including a reverse genetics approach, using MssI to remove elements not belonging to the viral genome, such as ori and resistance genes, and simultaneously linearizing the plasmid. The linearized plasmid is purified using a commercial purification and recovery kit to remove enzymes and other reaction components. 1-2 μg of the purified linearized plasmid is transfected into HEK293SF-3F6 cells grown in a 6-well plate using a Lipo2000 kit. The cells are then transferred to a T25 flask for culture the next day to remove the harmful Lipo2000 reagent and provide more room for cell growth. After 7 days, plaques of virus production can be observed, with cells detached from the plaques to form cavities.
[0076] Further methods for constructing recombinant adenoviruses containing viral or bacterial antigens include optimizing the viral or bacterial antigen gene, performing PCR experiments, and then recovering the product through enzymatic digestion to recover the digested fragments. Simultaneously, the plasmid vector is digested with the same endonuclease to recover the recombinant vector; this vector and the backbone plasmid are co-transfected into HEK293SF-3F6 cells for virus rescue. After 10-20 days, plaques of virus production can be observed, with cells shedding from the plaques to form cavities.
[0077] The following will clearly and completely describe the technical solutions of the present invention in conjunction with the embodiments of the present invention. Obviously, the embodiments described are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative efforts shall fall within the scope of protection of the present invention.
[0078] Example 1 Chimpanzee adenovirus vector ChAdOx1-HVR mutation (mutation regions in different HVR regions)
[0079] Based on the chimpanzee ChAdOx1 adenovirus vector, the following mutations were performed to study the charge effects of different HVR mutation regions on adenovirus titer and virus purification.
[0080] Table 1. Mutations in different HVR regions of chimpanzee adenovirus vector ChAdOx1
[0081] According to the experimental results in Figure 1, compared with the wild-type chimpanzee adenovirus ChAdOx1, the negative charge of ChAdOx1-Hexon_HVR mutation strategy 5 and ChAdOx1-Hexon_HVR mutation strategy 9 was reduced.
[0082] The virus titer results showed that the wild-type ChAdOx1 virus in group 1 had the highest titer, followed by groups 5 and 9-ChAdOx1-Hexon_HVR mutation strategy 5 and 9.
[0083] Example 2 Chimpanzee Adenovirus Vector ChAdOx1-HVR Mutation (HVR Region Combined Mutation)
[0084] Based on the chimpanzee ChAdOx1 adenovirus vector, the following mutations were performed to study the charge effects of combined mutations in the HVR2 and HVR7 regions on adenovirus titer and virus purification.
[0085] Table 2. Combination mutations in the HVR2 and HVR7 regions of chimpanzee adenovirus vector ChAdOx1
[0086] According to the experimental results in Figure 3, compared with the wild-type chimpanzee adenovirus ChAdOx1, the negative charge on the surface of the adenovirus in group 1-15-ChAdOx1-Hexon_HVR mutation strategy 16-30 was reduced.
[0087] The virus titer results in Figure 4 show that group 2-ChAdOx1-Hexon_HVR mutation strategy 17 has the lowest virus titer.
[0088] Example 3 Chimpanzee Adenovirus Vector ChAdOx1-HVR Mutation (HVR2 and HVR 7 Different Neutral Amino Acid Combination Mutations)
[0089] Based on the chimpanzee ChAdOx1 adenovirus vector, the following mutations were performed to study the effect of mutations in the HVR2 and HVR7 regions to different neutral amino acids on the charge of the adenovirus titer and virus purification.
[0090] Table 3. Combination mutations in the HVR2 and HVR7 regions of the chimpanzee adenovirus vector ChAdOx1 (different neutral amino acids)
[0091] According to the experimental results in Figure 5, compared with the wild-type chimpanzee adenovirus ChAdOx1, the negative charge on the surface of the adenovirus in group 1-9-ChAdOx1-Hexon_HVR mutation strategy 31-38 was reduced.
[0092] The viral titer results in FIG6 show that group 1-9-ChAdOx1-Hexon_HVR mutation strategy is basically the same as that of wild-type ChAdOx1 (Example Group 1), and replication is normal.
[0093] Example 4 Chimpanzee adenovirus vector ChAdOx1-HVR mutation (HVR2 and 7 combined with HVR1 and HVR5)
[0094] Based on the chimpanzee ChAdOx1 adenovirus vector, the following mutations were performed to study the effects of HVR2 and HVR7 regions combined with other combined mutations on adenovirus titer, charge during virus purification, and interaction with PF4.
[0095] Table 4. Chimpanzee adenovirus vector ChAdOx1 HVR1 / 2 / 5 / 7 combination mutations
[0096] According to the experimental results in Figure 7, compared with the wild-type chimpanzee adenovirus ChAdOx1, the negative charge on the surface of the adenovirus in group 1-12-ChAdOx1-Hexon_HVR mutation strategy 39-50 was reduced.
[0097] Figure 8 shows the results of the PF4 interaction experiment. The dissociation constant between ChAdOx1-Hexon_HVR mutation strategy 39-50 and PF4 increased, indicating that its interaction with PF4 decreased.
Claims
1. A recombinant adenovirus, characterized in that: One or more negatively charged amino acids in the hypervariable region HVR of the hexon protein of the adenovirus are mutated into neutral amino acids and / or positively charged amino acids.
2. The recombinant adenovirus according to claim 1, characterized in that The hypervariable region HVR of the hexon protein includes one or more of HVR1, HVR2, HVR3, HVR4, HVR5, HVR6, and HVR7.
3. The recombinant adenovirus according to claim 1 or 2, characterized in that: The mutation region of the hypervariable region HVR of the hexon protein at least includes HVR2 and / or HVR7.
4. The recombinant adenovirus according to any one of claims 1 to 3, characterized in that The negatively charged amino acid is aspartic acid D and / or glutamic acid E. The neutral amino acid is selected from one or more of valine V, leucine L, asparagine N, glutamine Q, and isoleucine I; and the positively charged amino acid is selected from one or more of arginine R, lysine K, and histidine H.
5. The recombinant adenovirus according to any one of claims 1 to 4, characterized in that At least one negatively charged amino acid in the hypervariable region HVR is mutated to a neutral amino acid.
6. The recombinant adenovirus according to any one of claims 1 to 5, characterized in that The mutation regions of the adenovirus hexon protein are: D144 and / or E159 of HVR1 or their equivalent positions; D171 and / or D175 and / or D177 of HVR2 or their equivalent positions; D265 of HVR5 or their equivalent positions; and / or D423 and / or D425 and / or E427 and / or E429 of HVR7 or their equivalent positions.
7. A method for producing the recombinant adenovirus according to any one of claims 1 to 6, characterized in that: The method comprises introducing the recombinant adenovirus into complementary cells, culturing the cells and harvesting the virus.
8. Use of the recombinant adenovirus according to any one of claims 1 to 6 in the preparation of a medicament, characterized in that: These include gene therapy, tumor immunization, and / or antiviral immunization.
9. Use of the recombinant adenovirus according to any one of claims 1 to 6 in the preparation of a medicament, characterized in that: The invention includes the use of eliciting a primary immune response in humans or mammals, eliciting a booster immune response or for destroying host tolerance to self-antigens.
10. A composition, characterized in that The method comprises the recombinant adenovirus according to any one of claims 1 to 6, and at least one heterologous transgene, wherein the heterologous transgene carries a viral or bacterial antigen.
11. A composition according to claim 10, characterized in that The viral or bacterial antigens are selected from: HIV, rabies virus, dengue virus, Ebola virus, coronavirus, human papillomavirus, hepatitis C virus, hepatitis B virus, rotavirus, measles virus, respiratory syncytial virus (RSV), herpes zoster virus (VZV), cytomegalovirus, herpes simplex virus type 2, Epstein-Barr virus, human metapneumovirus, parainfluenza virus, influenza virus, Trypanosoma cruzi and Plasmodium falciparum, Mycobacterium tuberculosis, Streptococcus pneumoniae, Moraxella catarrhalis, NTHi hemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Staphylococcus aureus, Helicobacter pylori, Chlamydia trachomatis or one or more.
12. The composition according to any one of claims 10 to 11, characterized in that It includes pharmaceutically acceptable excipients. Preferably, the pharmaceutically acceptable excipients are selected from one or more of a buffer, a protective agent, a stabilizer, a surfactant, an osmotic pressure regulator, an adjuvant, a preservative, and an inactivator.
13. The composition according to any one of claims 10 to 11, characterized in that The composition is a mucosal immune preparation, a humoral immune preparation, a cellular immune preparation, and a skin immune preparation.
14. The composition according to any one of claims 13, characterized in that Mucosal immunotherapy preparations are in the form of liquid, solid, semisolid, gas, and inhaled dosage forms.
15. A composition according to any one of claims 10-11, characterized in that The composition is a drug administration preparation. Preferably, the drug administration preparation is an intravenous injection, an intramuscular injection, a subcutaneous injection, an oral administration preparation, a buccal administration preparation, a sublingual administration preparation, a rectal administration preparation, a respiratory administration preparation, or a transdermal administration preparation; preferably, it is a respiratory administration preparation, which is an oral inhalation, a nasal inhalation, or an inhalation preparation after atomization by an atomization drug administration device.
16. Use of the composition according to any one of claims 10 to 15 in the preparation of a medicament, characterized in that: The medicament is used for one or more of the following purposes: gene therapy, tumor vaccination, antiviral vaccination, delivery of transgenes into host cells, for eliciting a primary immune response in humans or animals, for boosting an immune response in humans or animals, and for inducing an immune response in humans or animals that breaks tolerance to self-antigens.
17. A method for producing the composition according to any one of claims 10 to 15, characterized in that The invention comprises a nucleic acid providing a protein or a fragment thereof of a heterologous gene, allowing the recombinant adenovirus to proliferate in a host cell, isolating and purifying the recombinant adenovirus, and formulating the recombinant adenovirus into a pharmaceutically acceptable composition.
Citation Information
Patent Citations
Modulation of adenoviral tropism
CN102014948A
Adenoviruses and methods for using adenoviruses
US20200157510A1
Compositions and methods for inducing an immune response
WO2022084663A1
